Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Heska	Myriad Genetics	Lantheus	Celldex Therapeutics	Meridian Bioscience
Symbol	NASDAQ:HSKA	NASDAQ:MYGN	NASDAQ:LNTH	NASDAQ:CLDX	NASDAQ:VIVO
Price Information
Current Price	$176.98	$28.16	$21.04	$20.71	$25.04
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.0	1.7	1.8	1.7
Analysis Score	2.5	0.9	2.4	3.5	3.5
Community Score	2.4	1.9	2.5	3.1	1.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.6	1.9	0.6	1.3
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$217.50	$21.00	$23.67	$35.50	$33.00
% Upside from Price Target	22.90% upside	-25.43% downside	12.48% upside	71.41% upside	31.79% upside
Trade Information
Market Cap	$1.84 billion	$2.12 billion	$1.41 billion	$820.43 million	$1.08 billion
Beta	1.65	1.71	1.32	2.96	0.59
Average Volume	87,115	829,549	562,273	722,481	799,578
Sales & Book Value
Annual Revenue	$122.66 million	$638.60 million	$347.34 million	$3.57 million	$253.67 million
Price / Sales	15.03	3.32	4.06	229.81	4.26
Cashflow	$1.06 per share	$0.70 per share	$2.10 per share	N/A	$1.60 per share
Price / Cash	166.71	40.32	10.04	N/A	15.64
Book Value	$19.72 per share	$12.32 per share	$2.92 per share	$5.83 per share	$5.78 per share
Price / Book	8.97	2.29	7.21	3.55	4.33
Profitability
Net Income	$-1,470,000.00	$-199,500,000.00	$31.67 million	$-50,880,000.00	$46.19 million
EPS	$0.05	($0.35)	$1.17	($3.28)	$1.07
Trailing P/E Ratio	N/A	N/A	263.03	N/A	23.19
Forward P/E Ratio	N/A	N/A	42.94	N/A	23.40
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-11.15%	-32.49%	0.12%	-1,069.42%	18.21%
Return on Equity (ROE)	-2.29%	-4.07%	11.05%	-30.93%	21.06%
Return on Assets (ROA)	-1.64%	-2.68%	5.43%	-26.55%	12.55%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.18%	0.25%	0.40%	N/A	0.28%
Current Ratio	4.96%	2.95%	2.25%	16.63%	3.09%
Quick Ratio	3.79%	2.75%	1.79%	16.63%	1.92%
Ownership Information
Institutional Ownership Percentage	96.11%	96.72%	84.95%	80.15%	88.33%
Insider Ownership Percentage	11.70%	2.80%	2.08%	2.40%	2.00%
Miscellaneous
Employees	602	2,700	595	123	750
Shares Outstanding	10.42 million	75.21 million	67.03 million	39.62 million	43.15 million
Next Earnings Date	5/6/2021 (Confirmed)	5/4/2021 (Estimated)	4/29/2021 (Estimated)	5/5/2021 (Estimated)	5/14/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Meridian Bioscience: Good Stock, But Margin Of Safety Required seekingalpha.com - April 9 at 4:15 PM
	Meridian Bioscience (NASDAQ:VIVO) Downgraded by Zacks Investment Research marketbeat.com - April 8 at 6:44 AM
	Vivo X60 Pro is Now Available for Sale in Pakistan propakistani.pk - April 7 at 8:37 AM
	Meridian Bioscience Stock Shows Every Sign Of Being Modestly Overvalued gurufocus.com - April 7 at 3:34 AM
	Meridian Bioscience (NASDAQ:VIVO) Shares Down 3.6% americanbankingnews.com - April 6 at 12:02 PM
	vivo’s Latest 5G Flagship Smartphone X60 Pro is Now Available For Sale in Pakistan phoneworld.com.pk - April 6 at 7:11 AM
	4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic finance.yahoo.com - April 1 at 2:55 PM
	Meridian Bioscience (NASDAQ:VIVO) Shares Up 7.6% americanbankingnews.com - April 1 at 11:36 AM
	VIVO Cannabis(TM) Announces Fourth Quarter 2020 Results stockhouse.com - April 1 at 9:54 AM
	Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay finance.yahoo.com - April 1 at 9:54 AM
	IBD 50 Stocks To Watch: This Biotech Stock With 282% Earnings Growth Nears Buy Point finance.yahoo.com - March 31 at 6:52 PM
	Biomerica (NASDAQ:BMRA) versus Meridian Bioscience (NASDAQ:VIVO) Head to Head Survey americanbankingnews.com - March 27 at 8:20 PM
	Here's Why You Should Add Haemonetics (HAE) to Your Portfolio finance.yahoo.com - March 24 at 12:47 PM
	Meridian Bioscience Inc (VIVO) CEO John P. Kenny Sold $750,000 of Shares finance.yahoo.com - March 18 at 12:08 PM
	Don't Ignore The Fact That This Insider Just Sold Some Shares In Meridian Bioscience, Inc. (NASDAQ:VIVO) nasdaq.com - March 17 at 4:04 PM
	Meridian Bioscience (VIVO) Presents At H.C. Wainwright Global Life Sciences 2021 Virtual Conference - Slideshow seekingalpha.com - March 15 at 11:36 PM
	Meridian Bioscience's (VIVO) Shares March Higher, Can It Continue? finance.yahoo.com - March 11 at 1:32 PM
	Did You Miss Meridian Bioscience's (NASDAQ:VIVO) Impressive 189% Share Price Gain? finance.yahoo.com - March 9 at 12:49 PM
	Meridian Launches its New Air-Dryable Mix for Crude Blood Samples Nasdaq:VIVO compsmag.com - March 8 at 3:10 PM
	Meridian Launches its New Air-Dryable Mix for Crude Blood Samples finance.yahoo.com - March 8 at 10:10 AM
	Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference finance.yahoo.com - March 4 at 11:43 AM
	Here is Why Growth Investors Should Buy Meridian Bioscience (VIVO) Now finance.yahoo.com - March 1 at 5:20 PM
	Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal markets.businessinsider.com - February 23 at 5:39 PM
	SHAREHOLDER ALERT: Meridian Bioscience, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm finance.yahoo.com - February 23 at 5:39 PM
	Meridian Bioscience corrects prior update on Revogene sars-cov-2 EUA withdrawal seekingalpha.com - February 23 at 1:29 PM
	Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission finance.yahoo.com - February 23 at 12:38 PM

Date	Company	Brokerage	Action
3/3/2021	Heska	Raymond James	Boost Price Target
3/1/2021	Heska	Piper Sandler	Boost Price Target
2/24/2021	Heska	Alliance Global Partners	Reiterated Rating
1/29/2021	Heska	JPMorgan Chase & Co.	Initiated Coverage
3/27/2020	Heska	Sidoti	Lower Price Target
11/6/2019	Heska	Canaccord Genuity	Reiterated Rating
9/18/2019	Heska	Piper Jaffray Companies	Initiated Coverage
5/23/2019	Heska	Guggenheim	Initiated Coverage
2/27/2019	Heska	B. Riley	Lower Price Target
3/2/2021	Myriad Genetics	SVB Leerink	Boost Price Target
8/14/2020	Myriad Genetics	Needham & Company LLC	Reiterated Rating
4/2/2020	Myriad Genetics	Bank of America	Lower Price Target
3/26/2020	Myriad Genetics	Barclays	Lower Price Target
8/14/2019	Myriad Genetics	Deutsche Bank Aktiengesellschaft	Lower Price Target
3/4/2021	Lantheus	Credit Suisse Group	Boost Price Target
6/29/2020	Lantheus	Jefferies Financial Group	Initiated Coverage
6/16/2020	Lantheus	CJS Securities	Upgrade
8/2/2018	Lantheus	Wells Fargo & Company	Lower Price Target
3/1/2021	Celldex Therapeutics	HC Wainwright	Boost Price Target
2/23/2021	Celldex Therapeutics	Cantor Fitzgerald	Boost Price Target
11/17/2020	Celldex Therapeutics	Lifesci Capital	Reiterated Rating
8/9/2018	Celldex Therapeutics	Cowen	Reiterated Rating
5/11/2020	Meridian Bioscience	William Blair	Upgrade
4/3/2019	Meridian Bioscience	Robert W. Baird	Lower Price Target

(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources